occur via drug interactions with cytochrome P450 enzymes; antineoplastic medications that are entirely or partly metabolized by such enzymes include cyclophosphamide, taxanes, etoposide, irinotecan, aromatase inhibitors, vinca alkaloids, bicalutamide, imatinib, gefi tinib, and erlotinib ( 2 -7 ). A pharmaceutical interaction occurs when two chemically incompatible drugs are mixed before intravenous administration resulting in inactivation of one or both drugs ( 1 ) .
Several studies have evaluated the potential for drug interactions in general medicine. It was found in large surveys that approximately 60% of inpatients in general medical wards were at risk of drug interactions ( 8 -10 ) , and studies conducted in hospital emergency departments found that from 16% to 47% of patients were at risk of drug interactions ( 11 -13 ) . Among 103 outpatients screened by their family physician for the presence of drug combinations in which there was a potential for interaction, almost 70% had been exposed to such combinations ( 14 ) . An analysis of more than 5 million prescriptions in the French national healthcare system found that 2% of outpatients were exposed to either absolutely or relatively contraindicated drug combinations ( 15 ) . Finally, in a hospital-based retrospective study conducted in Norway, 18% of 732 deaths were associated, either directly or indirectly, with drug interactions ( 16 ) .
By contrast, few studies have addressed drug interactions in patients with cancer. In the Norwegian study ( 17 ) , 4% of cancerrelated deaths in hospitalized patients were associated with severe drug interactions ( 16 ) . In a previous study, we evaluated the frequency of drug combinations with potential to interact in cancer patients, but that study included only inpatients not currently receiving anticancer therapy ( 17 ) . We found that 63% of patients were exposed to drug combinations in which there was a potential for interaction. Because of the possible negative impact of drug interactions on patients and the paucity of literature on this topic in patients with cancer, we designed a cross-sectional study to evaluate the epidemiology of exposure to drugs with a potential to interact among ambulatory cancer patients receiving systemic anticancer therapy. The secondary objective was to evaluate the frequency and risk factors for duplicate prescribing in this population.
Patients and Methods

Study Design and Participants
This was a cross-sectional study undertaken at the Princess Margaret Hospital, Toronto, during an 8-month period (from September 2005 to May 2006). Princess Margaret Hospital is Canada's largest cancer center, in which more than 12 000 new patients were seen in 2005 across different clinics: radiation oncology, surgical oncology, medical oncology, malignant hematology, and palliative care. Our study was restricted to follow-up medical oncology clinics. Ambulatory adult patients with a diagnosis of solid malignancy and who were currently receiving standard systemic cancer-directed treatment were considered to be eligible. Patients receiving experimental agents, especially those in earlyphase clinical trials, were excluded because little is known about drug interactions with newer agents. Patients were not considered to be ineligible because of poor performance status, language barriers, or any other issue. Because all patients were on active cancerdirected therapy, all patients included in the study had an Eastern Cooperative Oncology Group performance status of 2 or less. Translators were available for patients who did not speak English.
Patients were recruited by one of the authors (R. P. Riechelmann) and a research assistant. To obtain a patient sample that was representative of all ambulatory cancer patients treated at the hospital, the recruiters rotated among the several follow-up medical oncology clinics at Princess Margaret Hospital on a biweekly basis. At the beginning of each clinic, the recruiters reviewed the clinic list with the responsible staff oncologist to identify eligible patients and to obtain permission to invite the patient to participate in the study. Because all eligible patients were on systemic treatment, they were being seen frequently in clinic. Therefore, by attending the same clinics on multiple occasions, the recruiters were able to ask all eligible patients to participate.
The study was approved by the Institutional Research Ethics Board, and written informed consent was obtained from all participants. Consenting patients were asked to complete a questionnaire (available online as Supplementary Data), either by themselves or with help from their caregiver. The four-page questionnaire collected data on age, sex, cancer diagnosis, and comorbid illnesses, as well as details of anticancer treatment. It also asked patients to list all medications (both enteral and parenteral agents administered at home or in the hospital) taken in the previous 4 weeks, along with the names of the respective prescribing physicians. Patients who did not remember all their current medications while completing the questionnaire received telephone follow-up calls within
CONTEXT AND CAVEATS
Prior knowledge
Cancer patients are often prescribed many medications concurrently; in addition to chemotherapeutic agents, they may receive drugs to treat non-neoplastic conditions as well as medicines for supportive care. The extent to which they are exposed to adverse drug interactions is unknown.
Study design
Information on individual exposure to various medications in a random sample of an outpatient population was collected by questionnaire, and potential drug interactions were identified using a software program that accessed published data on drug interactions.
Contribution
Potential interactions were identified in 27% of patients and classified according to severity, level of scientific evidence supporting the interaction, type of medications involved, type of cancer, and other parameters. Most of the potential interactions involved medications to treat comorbid conditions.
Implications
The results suggest the importance of further studies to determine the frequency of adverse drug interactions in cancer patients.
Limitations
The study was not designed to determine how often the potential drug interactions identified actually resulted in adverse clinical con sequences for patients. a week. Chart review was performed to confi rm and supplement information obtained from the questionnaire, such as anticancer regimen, treatment intent (palliative versus curative), and laboratory abnormalities. A laboratory abnormality was defi ned as an increase of 10% or greater above the upper normal limit in plasma levels of hepatic enzymes and creatinine measured within the prior 4 weeks (upper normal limits: aspartate transaminase ≤ 35 U/L, alanine transaminase ≤ 40 U/L, alkaline phosphatase ≤ 110, bilirubin ≤ 22 µ mol/L, creatinine ≤ 99 µ mol/L). If more than one blood test was done during this period, we chose the most abnormal result for analysis.
Drugs were classifi ed as either "supportive care agents" (defi ned as medications to treat cancer-and/or therapy-related symptoms) or "medications to treat comorbid conditions." A comorbid illness was defi ned as a noncancer clinical condition that required pharmacologic treatment. The number of medications for each patient was calculated by summing all medications except anticancer drugs; when a medication contained two or more pharmacologic compounds (e.g., acetaminophen combined with codeine), each drug was considered to be an individual drug in the analysis. However, when a patient was taking the same medication on more than one schedule (e.g., long-and short-acting morphine for pain control), that drug was counted only once.
Duplicate prescribing was considered to be present when two or more drugs from the same class were prescribed to treat the same condition (e.g., morphine and codeine prescribed as routine orders for pain) or different conditions (e.g., corticosteroids to prevent delayed nausea and as anti-infl ammatory agents).
Potential drug interactions were identifi ed using the Drug Interaction Facts software, version 4.0 ( 18 ) . If a drug was not recognized by the program, potential interactions were identifi ed manually by one of the authors (R. P. Riechelmann), using pharmacology textbooks. The Drug Interaction Facts software screens for potential drug interactions and, if one is identifi ed, provides a description of the pharmacologic mechanisms for the interaction and classifi es it as pharmacokinetic, pharmacodynamic, or, if there is not suffi cient evidence to support a known underlying pharmacologic mechanism, unknown. It also classifi es the interaction by level of severity and scientifi c evidence ( Table 1 ). In terms of severity, drug interactions were classifi ed as major, when the potential drug interaction could lead to permanent damage or risk of death; moderate, when the clinical consequence of an interaction required medical treatment; or minor, when small or no clinical effect was expected from the combination of two drugs. With respect to level of scientifi c evidence, potential drug interactions were classifi ed on a 5-point scale, with level 1 evidence meaning that a drug interaction was supported by large clinical trials and level 5 meaning that the risk for interaction between two drugs was only theoretical. The Drug Interaction Facts software had been found in a previous study to have both sensitivity and specifi city of 97% in detecting previously described/ known potential drug interactions ( 19 ) . We did not study potential interactions between drugs and complementary or alternative medications, herbs, or food because these were beyond the scope of this study and were not provided by the software. If a potentially serious drug interaction and/or duplicate medication was identifi ed, the prescribing physician was contacted.
Statistical Analyses
There were no data about drug interactions in oncology on which to base our sample size. Therefore, 400 patients were predefined and chosen as a feasible sample, and we approached patients until this number was enrolled. Summary statistics were used to describe patient characteristics (such as age, sex, cancer types, treatment intent, type of anticancer therapy, comorbid conditions, number of drugs per patient, type of medication taken by patients, and laboratory abnormalities); frequency, types and classification of drug interactions; and frequency with which medications were duplicated. Logistic regression was used to identify risk factors associated with potential drug interactions. The dependent variable was the number of potential drug interactions for which there was reasonable supportive evidence (i.e., scientific evidence levels 1 -3, Table 1 ). Explanatory variables were age, cancer type (breast, gastrointestinal, genitourinary, gynecologic, lung, brain, or other), treatment intent (palliative versus curative), treatment type (chemotherapy, hormone therapy, molecular agents, or combination), presence of at least one comorbid illness (yes/no), number of drugs (continuous variable), type of medications (supportive care agents, medications to treat comorbid conditions, or both), and presence of at least one laboratory abnormality (yes/no). Because some cancer types only occur in men or women, much of the information that sex would contribute to the regression analysis is implicit in cancer type; sex was not included as a potential risk factor, but cancer type was included. For binary variables, the group at lower risk of the outcome was chosen as the referent. Similarly, for other nominal variables, we also chose the group at least risk as the reference group. Variables with univariate P values that were less than .1 were entered into the multivariable model. Because of concerns that some variables may have been highly correlated, and therefore caused multicollinearity and violated a regression assumption, we constructed a correlation matrix and examined the variance inflation factors for each of the explanatory variables. These multicollinearity diagnostics did not indicate that multicollinearity was a problem in our final model. In multivariable analysis, both stepwise and backward selection techniques yielded the same results, so only results of the stepwise regression are presented. In the multivariable model, predictors were considered to be statistically significant if the P value was less than .05. The final model was adjusted for treatment intent as a proxy for disease severity. All statistical tests were two-sided.
Results
Characteristics of Patients
A total of 409 patients were initially identified as eligible; of these, two who had cognitive impairment and were considered to be ineligible by their staff oncologist were not asked to participate. Of the 407 patients invited to participate in the study, two subjects refused to participate. The remaining 405 patients completed the questionnaire and were included in the analysis; 399 (98.5%) of the questionnaires were fully completed. Six participants (1.5%) of 405 did not remember all their medications, and the missing information was collected by telephone within one week. The median age of participants was 58 years (range 21 -88 years); 64% were female and 36% were male ( Table 2 ). The most common cancer types were breast cancers (39%), gastrointestinal tumors (24%), and genitourinary cancers (16%). Sixty-two percent of patients were receiving anticancer therapy with palliative intent; 57% were receiving chemotherapy, 25% were being treated with hormone therapy, 7% were receiving molecular agents, and 11% were receiving more than one type of antineoplastic therapy. The median number of comorbid illnesses experienced by a patient was 1 (range = 0 -5), with cardiovascular diseases, musculoskeletal disorders, hypothyroidism, and depression being the most frequent. The median number of medications per patient was 5 (range 0 -23). Forty percent of patients were taking supportive medications only (mostly opioids, acetaminophen, antiemetic agents, steroids, stool softeners, and stomach protectors), 12% were receiving medications to treat comorbid illnesses exclusively, and 48% were receiving drugs for both purposes. Forty-six percent of patients had laboratory abnormalities, with liver dysfunction (affecting 28% of the patients) being the most common. A total of 276 potential drug interactions were identifi ed in 109 (27%; 95% confi dence interval [CI] = 23% to 31%) patients ( Table 3 ) ; interactions supported by at least several case reports (i.e., levels of scientifi c evidence < 3, Table 1 ) were identifi ed in 18% of patients. The majority of potential drug interactions were of moderate severity (77%), and 49% of them were supported by levels 1 or 2 scientifi c evidence, i.e., evidence to suggest that adverse effects were probable. Approximately half (55%) of the potential interactions were classifi ed as pharmacokinetic. Among the 276 potential interactions, 240 (87%) involved non-antineoplastic agents and 36 (13%) involved antineoplastic drugs.
The potential drug interactions between antineoplastic agents and common medications that were identifi ed are presented in Table 4 ; most of them involved warfarin, hydrochlorothiazide, or quinolones. The drug that was identifi ed most frequently as having potential for interaction with antineoplastic agents was warfarin; a potential for pharmacodynamic interaction of hydrochlorothiazide with cyclophosphamide and fl uorouracil was also common. Because of the extensive number of different potential interactions between non-antineoplastic medications, only the ones identifi ed most frequently are reported in Table 5 ; they involved, in order of decreasing frequency, antihypertensive agents (angiotensin-converting enzyme inhibitors [ACE inhibitors], beta-blockers, and hydrochlorothiazide), aspirin, warfarin, corticosteroids, phenytoin, and prochlorperazine.
A total of 390 patients were included in the logistic regression to determine risk factors associated with potential drug interactions; 15 patients who were currently not receiving other medications besides those used in systemic anticancer treatment were excluded from analysis because they were not at risk of potential , 95% CI = 2.9 to 25, P <.001, OR, both types of medications versus supportive care drugs: 2.5, 95% CI = 1.2 to 5.5, P = .018) showed a statistically signifi cant association with the drugs with potential to interact for which there was reasonable supportive evidence (i.e., scientifi c evidence levels 1 -3, Table 1 ).
Duplicate Prescribing
Thirty-two (8%) patients were exposed to duplicate prescribing. Three of these patients had two instances of duplicate prescriptions. Most cases of duplicated medications were due to duplication of corticosteroids (16 cases), with the majority of these caused by prescription of dexamethasone for prevention of docetaxelrelated reactions and prednisone to treat prostate cancer. Of the duplicate prescriptions not involving corticosteroids, seven were of proton pump inhibitors, six were of benzodiazepines, and four were of opioids. There was one duplication each of antidepressants and bisphosphonates. 
Discussion
Our study demonstrates that the frequency of drug combinations in which there is potential for harmful interaction was high in the ambulatory cancer patients in our study, with about one-third of patients being exposed to at least one interaction. Drug combinations for which there were potential interactions supported by a level of scientific evidence of 3 or less (i.e., scientific evidence supported by at least several case reports) were prescribed to 18% of patients. These rates are of concern because 86% of all interactions were classified as major or moderate, and almost 50% of them were supported by level 1 -2 scientific evidence (i.e., evidence from clinical trials). The large majority of potential drug interactions were due to the presence of non-anticancer agents (87%); most often these were antihypertensive agents, aspirin, warfarin, or anticonvulsants. Potential drug interactions due to the presence of anticancer agents most often also involved warfarin, whose anticoagulant effects are increased by anticancer agents ( 20 -24 ) , or hydrochlorothiazide, whose interaction with anticancer drugs may prolong neutropenia ( 25 ) . Factors such as increasing number of medications, the presence of certain tumor types, and receipt of medications for comorbid illness as opposed to drugs for cancer-or treatment-related symptoms were associated with increased risk of potential drug interactions. * ASA = acetylsalicylic acid; ACE = angiotensin-converting enzyme; SSRI = selective serotonin reuptake inhibitor; NSAID = nonsteroidal anti-inflammatory drug. † Lower number indicates greater strength of evidence in support of drug interaction. Exact definitions of each category are given in Table 1 .
A retrospective pilot study undertaken by two of the authors of this study reported potential drug interactions in 63% of 100 consecutive inpatients not receiving anticancer therapy ( 17 ) . In that study, which utilized the same electronic screening method as the present investigation, 75% of potential interactions were classifi ed as major or moderate. A Norwegian study found that 4% of cancer-related deaths in hospitalized patients were likely to be associated with severe interactions ( 16 ) . We are unaware of other studies that have evaluated the epidemiology of potential drug interactions among ambulatory cancer patients receiving antineoplastic therapy.
The fi nding that increasing number of medications was a risk factor for potential drug interactions in our population is consistent with previous studies ( 9 , 12 , 26 ) and is not surprising. Also, patients with brain tumors were more likely to be exposed to drug combinations for which there were potential drug interactions compared to patients with other tumor types; this was probably because brain tumor patients often use anticonvulsants. Since the majority of potential drug interactions involved antihypertensive agents, aspirin, and warfarin, it is not surprising that the odds of being exposed to a potential drug interaction were eight times greater for patients receiving medications to treat comorbid conditions than for patients receiving only drugs for supportive care.
The type of antineoplastic therapy was not a predictive factor for potential drug interactions.
Our study is limited by the fact that it was performed in a single institution; thus, its external validity is unknown. However, the internal validity should be high because we systematically collected the names of all medications and tried to recruit consecutive eligible patients as often as possible to limit selection bias. Another limitation of our study is that, because of its high sensitivity ( 19 ) , the screening software was capable of detecting the majority of drug interactions, including those supported by lower levels of evidence and those for which the clinical consequences are unknown.
The major limitation of our study is lack of information about the number instances in which drug combinations with potential interactions resulted in clinical consequences. We attempted to collect information on real drug interactions by asking patients about hospitalization and causes thereof during the 12 months before the completion of the questionnaire. However, it was difficult to obtain reliable information in part because Princess Margaret Hospital is a tertiary referral center and patients come from a wide encatchment area. Therefore, most admissions are to community hospitals closer to the patient's residence. Furthermore, there is an inherent bias in studies evaluating real drug interactions because if a drug interaction that led to serious clinical consequences has already occurred, adjustment in prescribing is likely to have taken place. Also, when we identifi ed potentially lifethreatening interactions, the primary oncologist was contacted, and, in most cases, treatment modifi cations were made to prevent adverse clinical events.
The most commonly used drug with potential for interaction with antineoplastic agents was warfarin. The combination of warfarin with fl uorouracil, capecitabine, etoposide, carboplatin, paclitaxel, or gemcitabine may cause hemorrhage due to chemotherapy-induced serum protein displacement (higher volume of distribution of warfarin) and/or interference with warfarin hepatic metabolism ( 20 -24 ) . This fi nding is important because all of the above potential interactions are supported by level 2 sci entifi c evidence for their occurrence and are of moderate severity. A frequently identifi ed potential pharmacodynamic interaction was due to the concurrent administration of hydrochlorothiazide with cyclophosphamide and fl uorouracil ( Table 4 ) . This potential interaction, although supported only by level 4 scientifi c evidence (i.e., a few case reports), may lead to prolonged and severe neutropenia ( 25 ) . Among potential interactions with non-anticancer drugs, the most commonly identifi ed were those between aspirin and ACE inhibitors or beta-blockers || A laboratory abnormality was defined as an increase of 10% or greater than a prespecified upper normal limit.
and between aspirin and corticosteroids, all supported by level 2 evidence. In the presence of aspirin, the hypotensive effects of ACE inhibitors and/or beta-blockers may be impaired because of decreased synthesis of prostaglandins caused by aspirin ( 27 -29 ) . The increased hepatic metabolism and renal excretion of aspirin induced by corticosteroids may lead to reduction of plasma levels of aspirin levels and consequently, less clinical effect ( 30 ) . Although identifi cation of real drug interactions was not formally part of this study, we saw clear evidence for them. For instance, two patients who were taking long-term warfarin with a stable international normalized ratio of between 2.0 and 3.0 experienced an increase of more than 50% in the international normalized ratio after prescription of capecitabine ( 21 ) . A patient receiving adjuvant fl uorouracil for stage III colon cancer experienced prolonged neutropenia after being prescribed cimetidine during the fourth cycle of chemotherapy ( 31 ) . Furthermore, a patient receiving a short-term nonsteroidal anti-infl ammatory drugs together with a serotonin-selective reuptake inhibitor was admitted because of upper gastrointestinal bleeding ( 32 ) . Descriptions of these probable drug interactions are detailed in Tables 4 and 5 .
The best way to prevent drug interactions is unknown. Alert guidelines, such as electronic alerts that appear when health professionals enter patients' medication orders into the electronic medical record, or fl yers to remind physicians and pharmacists of drugs with potential to interact could be developed to help identify potentially hazardous interactions. Computerized programs can increase recognition of such interactions and can provide an important tool for screening them ( 33 ) . We suggest that patients at high risk, such as those with comorbid conditions or brain tumors and particularly those receiving warfarin, anticonvulsants, and antihypertensive medications be routinely screened for potential drug interactions. The development of medication databases and computerized physician medication order entry linked to screening electronic programs could help health professionals to identify dangerous drug combinations and monitor prescriptions of agents with high risks of interactions such as anticonvulsants and warfarin. These tools would also allow for easy identifi cation of patients whose prescriptions contain numerous medications.
In our study, the frequency of duplicated medications was low and mostly due to coprescribing of dexamethasone and prednisone, ranitidine/famotidine and omeprazole, or benzodiazepines and opioids. The clinical impact of duplicate prescribing of steroids and stomach protectors is perhaps low, since dexamethasone was usually given for 2 -3 days to prevent docetaxel-related hypersensitivity reactions or delayed nausea/vomiting. The coadministration of omeprazole and ranitidine/famotidine is not likely to lead to major consequences. However, duplicate prescribing of benzodiazepines and opioids can be hazardous.
In conclusion, potential drug interactions are frequent in oncology and many are clinically important. Population-based studies are needed to assess the prevalence of "real" drug interactions. Development of alert guidelines and computer-based screening would help physicians to recognize and prevent potentially dangerous drug interactions.
